Victoria Socha

DocwireNews

American Transplant Congress 2021Researchers, led by S. Ismail, conducted a systematic review of published literature on clinical outcomes and management of adult kidney transplant recipients with COVID-19 with an eye toward synthesis of the evidence available on therapeutic interventions and clinical outcomes in that patient population. Results of the review were reported during a virtual session at the 2021 American Transplant Congress in a presentation titled Clinical Outcomes and Management of COVID-19 Patients among Kidney Transplant Recipients: A Systematic Review.The literature search included PubMed, EMBASE,, and the Cochrane registry for systematic reviews, as well as clinicaltrials.gov. There was no language restriction and articles of interest were published from November 1, 2019, to August 13, 2020. Studies of other organ transplants or dual organ transplants were excluded. The primary outcome of interest was the use of therapeutics for the treatment of COVID-19, alterations of immunosuppressive regimens, and clinical progression among kidney transplant recipients with COVID-19.The search identified 90 eligible studies representing 1052 <a href="https://www.docwirenews.com/latest-nephrology-news/outcomes-among-kidney-transplant-recipients-with-covid-19-2/">kidney transplant recipients</a>. Of those, 68 were case reports or case series, representing 155 kidney transplant recipients. Among the 155 patients, 44 received intravenous steroids and 55% continued their oral maintenance steroid doses. Aminoquinolines, azithromycin, antivirals, and tocilizumab were used for 100, 64, 38, and 24 kidney transplant recipients, respectively. Acute kidney injury (AKI) occurred in 56.5%; 15 required renal replacement therapy (RRT). Twenty-five patients were admitted to the intensive care unit (ICU); median length of stay in the ICU was 10 days. Median length of hospital stay was 17 days. Death occurred in 22.6% of patients. Antimetabolites were withheld or doses reduced in 90.9% of patients.The search also identified 23 aggregate-level studies, representing 897 kidney transplant recipients. Among those patients, 26.5% died and 35.11% developed AKI, 37 of whom required RRT. Hydroxychloroquine, azithromycin, and tocilizumab were used for 813, 491, and 373 kidney transplant recipients, respectively. Antimetabolites were stopped in 51.2%, calcineurin inhibitors were stopped or doses reduced in 320 patients, and steroid dose was increased in 222 patients.&ldquo;Kidney transplant recipients diagnosed with COVID-19 present a vulnerable population with high risk of severe clinical outcomes, including AKI, ICU admission, and mortality. A careful risk-benefit assessment between the use of antiviral drugs and the interruption of maintenance immunosuppressive agents including steroids is likely to be an important factor in the treatment of COVID-19 in this group,&rdquo; the researchers said.Source: Ismail S, Banonj A, Harbi S Al, Babonj A, Almalki A, Murray E.J. Clinical outcomes and management of COVID-19 patients among kidney transplant recipients: A systematic review. Abstract of a presentation at the virtual American Transplant Congress 2021 (abstract #787), June 6, 2021.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Outcomes among Kidney Transplant Recipients with COVID-19

American Transplant Congress 2021

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe